|
Market Closed -
Nasdaq
23:00:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.070 USD | -13.01% |
|
+10.31% | -86.26% |
Company Valuation: Decoy Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 22.39 | 3.485 | 2.56 | 2.652 | 4.142 | 0.701 | - |
| Change | - | -84.43% | -26.55% | 3.58% | 56.21% | -83.07% | - |
| Enterprise Value (EV) | 22.39 | 3.485 | 2.56 | 2.652 | 4.142 | 0.701 | 0.701 |
| Change | - | -84.43% | -26.55% | 3.58% | 56.21% | -83.07% | 0% |
| P/E | -1.6x | - | -0.17x | -0.32x | -0.06x | -0.12x | -0.13x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | - | 0x | 0x | 0x | 0.02x |
| Capitalization / Revenue | 12,167,670x | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | -0x | -0.07x | -0.04x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -11,160 | - | -5,530 | -1,042 | -129.1 | -8.96 | -8.28 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales | 1.84 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | -12.61 | -10.2 | -19.1 |
| Net income 1 | -12.77 | -31.61 | -12.54 | -5.576 | -12.52 | -10.1 | -19.1 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 17,841.586 | 2,203.200 | 936.000 | 331.200 | 7.786 | 1.070 | 1.070 |
| Nbr of stocks (in thousands) | 1.26 | 1.58 | 2.74 | 8.01 | 532 | 655.2 | - |
| Announcement Date | 3/10/22 A | 3/27/23 A | 3/22/24 A | 3/21/25 A | 3/31/26 A | - | - |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.12x | - | - | - | 701K | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.85x | 0.86% | 54.62B | |
| 34.93x | 3.32x | 14.34x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -64.56x | 13.05x | -73.23x | -.--% | 24.7B | |
| Average | 16.31x | 28.02x | 6.57x | 0.34% | 39.43B | |
| Weighted average by Cap. | 22.09x | 26.34x | 10.94x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- DCOY Stock
- Valuation Decoy Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
